This disease usually is screened and diagnosed with blood‐based biomarkers (alanine aminotransferase, aspartate aminotransferase, and GGT), imaging‐based technology (ultrasonography, magnetic resonance imaging, and controlled attenuation parameter), or estimation equations (FLI, HSI, NAFLD liver fat score, and SteatoTest) (National Guideline Centre (UK), NICE Guideline, No. 49., 2016). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.